Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00093093 | Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive | PHASE3 | COMPLETED | 900 | — | — | Jun 1, 2004 | May 1, 2006 | Jun 22, 2012 | 100 | United States, Argentina +10 |
| NCT00230958 | Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive | PHASE3 | COMPLETED | 900 | — | — | Dec 1, 2003 | Jan 1, 2006 | Jun 22, 2012 | - | — |
| Name | Type | Description |
|---|---|---|
| Viramidine | DRUG | - |
| Ribavirin | DRUG | - |
| pegylated interferon alfa-2a | DRUG | - |
| pegylated interferon alfa-2b | DRUG | - |
Inclusion Criteria: * Treatment-naive patients with compensated chronic hepatitis C. * HCV RNA \>2000 copies/mL (780 IU/mL) as determined by NGI SuperQuant serum HCV RNA quantification, with a lower limit of detection of 100 copies/mL (39 IU/mL). Exclusion Criteria: * Severe neuropsychiatric diso...